CRESCENT BIOPHARMA, INC.
For the period ended Jun 30, 2025. Filed Jul 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 31, 2025
CBIO$13.65+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report are set forth below.
| ExhibitNumber | Description | Form | Exhibit | Filing Date |
|---|---|---|---|---|
| 2.1† | Agreement and Plan of Merger and Reorganization, dated as of October 28, 2024, by and among GlycoMimetics, Inc., Gemini Merger Sub Corp., Gemini Merger Sub II, LLC, and Crescent Biopharma, Inc. | 8-K | 2.1 | October 29, 2024 |
| 2.2† | Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of February 14, 2025 | 8-K | 10.1 | 2/14/2025 |
| 2.3† | Amendment No. 2 to Agreement and Plan of Merger and Reorganization, dated as of April 28, 2025, by and among GlycoMimetics, Inc., Gemini Merger Sub Corp., Gemini Merger Sub II, LLC, and Crescent Biopharma, Inc. | 8-K | 10.1 | April 29, 2025 |
| 3.1 | Memorandum and Articles of Association | 8-K | 3.4 | June 18, 2025 |
| 3.2 | Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Shares | 8-K | 3.6 | June 18, 2025 |
| 4.1 | Form of Pre-funded Warrant | 8-K | 4.1 | June 18, 2025 |
| 10.1††† | CR-001 License Agreement, dated April 28, 2025, by and between Paragon Therapeutics, Inc. and Crescent Biopharma, Inc. | S-4 | 10.52 | April 29, 2025 |
| 10.2††† | Amended and Restated ADC Discovery and Option Agreement, dated April 28, 2025, by and among Paragon Therapeutics, Inc., Parascent Holding LLC and Crescent Biopharma, Inc. | S-4 | 10.53 | April 29, 2025 |
| 10.3 | Sublease, dated as of May 28, 2025, by and between Crescent Biopharma, Inc. and Nano Dimension USA Inc. | 8-K | 10.20 | June 18, 2025 |
| 10.4# | Crescent Biopharma, Inc. 2025 Stock Incentive Plan | 8-K | 10.7 | June 18, 2025 |
| 10.5# | Crescent Biopharma, Inc. 2025 Employee Stock Purchase Plan | 8-K | 10.8 | June 18, 2025 |
| 31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) promulgated under the Securities Exchange Act of 1934 | |||
| 31.2* | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) promulgated under the Securities Exchange Act of 1934 | |||
| 32.1** | Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(B) promulgated under the Securities Exchange Act of 1934 | |||
| 32.2** | Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(B) promulgated under the Securities Exchange Act of 1934 | |||
| 101.INS | Inline XBRL Instance Document. | |||
| ExhibitNumber | Description | Form | Exhibit | Filing Date |
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document. | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in exhibit 101). | |||
| * | Filed herewith. |
|---|---|
| ** | Furnished herewith. |
| # | Indicates management contract or compensatory plan or arrangement. |
| † | Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished. |
| †† | Certain portions of this exhibit (indicated by “[***]”) have been omitted because they are both (i) not material and (ii) customarily and actually treated as private or confidential. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.